AXIM® Biotechnologies, Inc. (OTC:AXIM)

AXIM® Biotechnologies, Inc. (OTC:AXIM) has developed a cannabinoid-based solution for the treatment of psoriasis and eczema, two debilitating skin conditions for which there are currently no effective treatments, or the ones available are associated with significant side effects. The Company’s breakthrough, patent-pending ointment uses stem cell cannabinoid cannabigerol (CBG), which is known for its chief anti-inflammatory properties.

Psoriasis and eczema are expected to affect nearly two hundred million people across the world by the year 2024, with a combined market estimated to reach $16 billion by 2022. This growing patient population presents a great need for reliable treatment options that do not have the serious side effects that exist with many existing prescription treatments.

Human dermatological clinical trials have begun in the Netherlands at the Maurits Clinic in the Hague by Dr. Marcus Meinardi. In conjunction with Axim Biotech, Dr. Meinardi will be working towards developing treatment applications for Axim’s AX-1602 ointment. Since CBG is a stem cell cannabinoid, it’s effective at changing the appearance and health of skin at the cellular level. It is also highly effective in the treatment of chronic conditions, such as psoriasis.

AXIM Biotech CEO Dr. George Anastassov explains that the company is pleased with the current progress of the clinical trials. Atopic dermatitis and psoriasis both cause serious quality of life issues, leading to physical and psychological discomfort among patients. The proprietary technologies utilized by AXIM Biotech will provide a greater variety of treatment options for sufferers of these conditions to explore. Some patients respond better to topical treatments than others, so variety of application is the key to addressing the needs of all patients.

Dr. Meinardi has extensive professional experience in the field of dermatological treatment options, making his skills a natural match for AXIM Biotech’s wealth of cannabinoid testing resources. The focus of the current initiative is on developing safe and effective solutions for those with serious skin disorders of the most common types, but future applications could address even more conditions.

Psoriasis is an immune disorder that affects more than 125 million people worldwide. This condition causes large skin lesions that peel, scale and often cause pain. Symptoms of psoriasis can lead to serious physical and psychological effects, but there are few products on the market that fully treat the condition. Eczema, also known as atopic dermatitis, is an inflammatory skin condition that causes itchy, red and swollen skin. When the skin cracks, it can cause pain and result in clear fluid seeping from the affected area. Children with the disorder are more likely to experience full-body skin irritation, which makes eczema a potentially debilitating condition. Eczema patients are also more likely to develop skin infections, which can become dangerous if left untreated.

AXIM Biotech is a Manhattan-based company that has developed such innovative technologies as cannabis-based chewing gum. The chewing gum, MedChew RX™, is designed to treat symptoms of multiple sclerosis, a debilitating condition that causes serious discomfort and physical limitations. This product is still in the pre-clinical stage of development, but it is expected to change the lives of the 400,000 multiple sclerosis sufferers in the United States once it is released. MedChew RX™ is the world’s first patented controlled-release chewing gum with a cannabinoid base. This product is expected to outperform the sublingual spray that is currently on the market. The chewing gum has a market potential of $4.8 billion dollars and is set to be FDA registered by the end of 2017.

With promising clinical trials in progress, AXIM Biotech is an industry leader when it comes to developing safe and effective pharmaceutical treatments for skin ailments. CBG is a highly versatile substance and because it does not have any psychoactive properties, it is a viable treatment option for most patients. As AXIM Biotech continues to release new treatment options, patients with chronic skin conditions around the world will benefit from the improved selection of products.

About the Author

Stuart Smith is the CEO and Founder of SmallCapVoice.com. SmallCapVoice.com. is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients’ financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks they are interested in. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in stocks that are traded on the OTC BB and Pink Sheets. To learn more about SmallCapVoice.com and their services, please visit http://smallcapvoice.com/blog/the-small-cap-daily-small-cap-newsletter/